Literature DB >> 21941230

Sildenafil citrate, bronchopulmonary dysplasia and disordered pulmonary gas exchange: any benefits?

M Nyp1, T Sandritter, N Poppinga, C Simon, W E Truog.   

Abstract

OBJECTIVE: The objective of this study is to determine the effects that sildenafil citrate has on gas exchange in infants with bronchopulmonary dysplasia (BPD)-associated pulmonary hypertension (PH). STUDY
DESIGN: A retrospective review was performed from 2005 to 2009. Infants treated with sildenafil citrate for greater than 48  h were included. Standard patient data was collected, including echocardiogram, inspired oxygen and systemic blood pressure, before and during administration of sildenafil citrate. RESULT: Sildenafil citrate was used in 21 preterm infants with BPD-associated PH. A significant reduction in estimated right ventricular peak systolic pressure was seen after initiation of sildenafil citrate, with the majority of infants showing no improvement in gas exchange at 48  h of treatment. Four infants died during treatment.
CONCLUSION: Sildenafil citrate reduced estimated pulmonary artery pressures, but this reduction was not reflected in improved gas exchange within the first 48  h.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21941230     DOI: 10.1038/jp.2011.131

Source DB:  PubMed          Journal:  J Perinatol        ISSN: 0743-8346            Impact factor:   2.521


  30 in total

Review 1.  Frontiers in pulmonary hypertension in infants and children with bronchopulmonary dysplasia.

Authors:  Joseph M Collaco; Lewis H Romer; Bridget D Stuart; John D Coulson; Allen D Everett; Edward E Lawson; Joel I Brenner; Anna T Brown; Melanie K Nies; Priya Sekar; Lawrence M Nogee; Sharon A McGrath-Morrow
Journal:  Pediatr Pulmonol       Date:  2012-07-06

2.  More safety data: what about efficacy of sildenafil?

Authors:  K König
Journal:  J Perinatol       Date:  2016-02       Impact factor: 2.521

Review 3.  Therapies that enhance pulmonary vascular NO-signaling in the neonate.

Authors:  Julie Dillard; Marta Perez; Bernadette Chen
Journal:  Nitric Oxide       Date:  2019-12-20       Impact factor: 4.427

4.  Pulmonary hypertension in premature infants. Sharpening the tools of detection.

Authors:  Kathryn N Farrow; Robin H Steinhorn
Journal:  Am J Respir Crit Care Med       Date:  2015-01-01       Impact factor: 21.405

5.  Sildenafil for the Treatment of Pulmonary Arterial Hypertension in Infants with Bronchopulmonary Dysplasia.

Authors:  M N Trottier-Boucher; A Lapointe; J Malo; A Fournier; M J Raboisson; B Martin; A Moussa
Journal:  Pediatr Cardiol       Date:  2015-04-01       Impact factor: 1.655

6.  Looking beyond PPHN: the unmet challenge of chronic progressive pulmonary hypertension in the newborn.

Authors:  Candice D Fike; Judy L Aschner
Journal:  Pulm Circ       Date:  2013-11-19       Impact factor: 3.017

Review 7.  Safety of sildenafil in infants*.

Authors:  Samira Samiee-Zafarghandy; P Brian Smith; Johannes N van den Anker
Journal:  Pediatr Crit Care Med       Date:  2014-05       Impact factor: 3.624

Review 8.  An update on pharmacologic approaches to bronchopulmonary dysplasia.

Authors:  Sailaja Ghanta; Kristen Tropea Leeman; Helen Christou
Journal:  Semin Perinatol       Date:  2013-04       Impact factor: 3.300

Review 9.  Pulmonary Hypertension and Vascular Abnormalities in Bronchopulmonary Dysplasia.

Authors:  Peter M Mourani; Steven H Abman
Journal:  Clin Perinatol       Date:  2015-09-26       Impact factor: 3.430

Review 10.  Pharmacologic strategies in neonatal pulmonary hypertension other than nitric oxide.

Authors:  Satyan Lakshminrusimha; Bobby Mathew; Corinne L Leach
Journal:  Semin Perinatol       Date:  2016-01-14       Impact factor: 3.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.